BI 685509, Placebo to BI 685509 clinical trials

A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis

This study is testing a new tablet called BI 685509 for adults with a condition called systemic sclerosis. It aims to see if the tablet can slow down lung damage and improve other symptoms, compared to a dummy pill.